Valuation: MannKind Corporation

Market Cap 1.08B 947M 896M 813M 1.53B 103B 1.54B 10.72B 4.14B 52.75B 4.04B 3.96B 170B P/E 2026 *
-18.4x
P/E 2027 * -2,680x
Enterprise Value 1.08B 947M 896M 813M 1.53B 103B 1.54B 10.72B 4.14B 52.75B 4.04B 3.96B 170B EV / Sales 2026 *
2.43x
EV / Sales 2027 * 2.14x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day+0.30%
1 week-5.37%
Current month-16.46%
1 month-17.49%
3 months-19.08%
6 months+46.93%
Current year-40.92%
1 week 3.17
Extreme 3.17
3.55
1 month 3.17
Extreme 3.17
4.36
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 2017-05-24
Director of Finance/CFO 50 2024-04-21
Chief Tech/Sci/R&D Officer - 2025-09-28
Director TitleAgeSince
Director/Board Member 82 2003-09-30
Director/Board Member 82 2003-11-30
Chairman 69 2020-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Sell

Director

-33,558 0.0104%
8/7/26 Sell

Director

-39,051 0.0122%
7/17/26 Sell

General Counsel

-24,109 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%-5.37%-39.42%-18.29% 1.07B
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-3.08%+37.74%+84.21% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-1.94%-14.13%+354.32% 25.73B
+0.57%+3.14%+1.02%-3.92% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+0.02%+49.51%+163.05% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.17%-0.69%+29.76%+146.78% 27.62B
Weighted average by Cap. -0.12%-1.07%+37.83%+124.73%

Financials

2026 *2027 *
Net sales 443M 390M 369M 335M 629M 42.56B 632M 4.42B 1.7B 21.72B 1.66B 1.63B 69.8B 504M 443M 419M 380M 714M 48.37B 718M 5.02B 1.94B 24.68B 1.89B 1.85B 79.33B
Net income -57.18M -50.28M -47.56M -43.14M -81.05M -5.49B -81.49M -569M -220M -2.8B -215M -210M -9B 27.12K 23.85K 22.56K 20.46K 38.44K 2.6M 38.65K 270K 104K 1.33M 102K 99.61K 4.27M
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
26-09-28 US$3.350 +0.30% 2,077,288
26-09-25 US$3.340 +1.52% 8,853,613
26-09-24 US$3.290 -1.50% 2,964,534
26-09-23 US$3.340 -4.30% 2,877,455
26-09-22 US$3.490 -0.29% 16,303,712
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.340USD
Average target price
7.969USD
Spread / Average Target
+138.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock